Article

FDA Approves Drug for Adult Insomnia

Author(s):

Lemborexant (brand name DAYVIGO™) has been approved by the FDA for the treatment of insomnia in adults.

The U.S. Food and Drug Administration (FDA) has approved lemborexant (brand name DAYVIGO™) for the treatment of adult insomnia. The dosage will be prescribed in 5 mg and 10 mg tabs for patients who struggle with falling asleep or maintaining sleep.

According to a press release, "the approval was based on a robust clinical development program that included two pivotal Phase 3 studies, which evaluated DAYVIGO versus placebo for up to one month and DAYVIGO versus placebo for six months."

There are potential risks, however, and a submission was made to the U.S. Drug Enforcement Administration (DEA) that will classify lemborexant as a controlled substance.

Lemborexant will be commercially available as DAYVIGO by manufacturer Eisai Co., Ltd., "following scheduling by the DEA, which is expected to occur within 90 days."

Related Videos
Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA
Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA
Chelsie Monroe, MSN, APN, PMHNP-BC, and Karl Doghramji, MD, FAASM, DFAPA
sleep
© 2024 MJH Life Sciences

All rights reserved.